Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Influenza, Human 1Hemangiosarcoma 1Carcinoma, Squamous Cell 1

Interventions

Cisplatin 5Cetuximab 3Radiotherapy 2Petrolatum 2Nivolumab 2Magnetic Resonance Spectroscopy 2Fluorouracil 2temoporfin 1talazoparib 1ruxolitinib 1peginterferon alfa-2a 1olaparib 1fluoromisonidazole 1fludarabine phosphate 1fludarabine 1decitabine and cedazuridine drug combination 1cemiplimab 1cedazuridine 1atezolizumab 1aldesleukin 1Vorinostat 1Sorafenib 1Radiotherapy, Intensity-Modulated 1Radiation 1Narrow Band Imaging 1Interviews as Topic 1Interleukin-2 1Gefitinib 1Decitabine 1DNA 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Carcinoma, Squamous Cell × peginterferon alfa-2a × Clear all
NCT05729139 2023-08-09

Cemiplimab/Peg-Interferon-α in Advanced CSCC

Baptist Health South Florida

Phase 1 Withdrawn
Tumor-Agnostic

Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡